Clinical Trial Update: A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation study of gefapixant (MK-7264) in refractory chronic cough completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• AF-219
• Gefapixant (gefapixant)
• MK-7264 (MK-7264)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2020-10-22